Farallon Capital Management LLC lifted its holdings in shares of Zogenix, Inc. (NASDAQ:ZGNX) by 165.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 850,000 shares of the company’s stock after acquiring an additional 530,000 shares during the period. Farallon Capital Management LLC owned approximately 2.48% of Zogenix worth $34,043,000 at the end of the most recent reporting period.
Several other large investors have also bought and sold shares of ZGNX. Cubist Systematic Strategies LLC purchased a new position in Zogenix in the third quarter valued at about $226,000. Sterling Capital Management LLC purchased a new stake in shares of Zogenix during the 3rd quarter valued at approximately $237,000. Teacher Retirement System of Texas bought a new stake in Zogenix during the 4th quarter worth approximately $409,000. Stifel Financial Corp bought a new stake in Zogenix during the 2nd quarter worth approximately $175,000. Finally, Voya Investment Management LLC increased its holdings in Zogenix by 13.5% during the 2nd quarter. Voya Investment Management LLC now owns 14,147 shares of the company’s stock worth $205,000 after acquiring an additional 1,686 shares during the period.
Zogenix, Inc. (ZGNX) remained flat at $$44.50 during trading hours on Wednesday. 211,756 shares of the stock were exchanged, compared to its average volume of 602,247. Zogenix, Inc. has a 52-week low of $10.00 and a 52-week high of $45.85. The firm has a market capitalization of $1,530.00, a P/E ratio of -12.63 and a beta of 1.57.
Zogenix (NASDAQ:ZGNX) last posted its quarterly earnings data on Tuesday, March 6th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.17). Zogenix had a negative return on equity of 81.65% and a negative net margin of 309.76%. During the same quarter in the previous year, the company posted ($0.95) earnings per share. analysts forecast that Zogenix, Inc. will post -3.12 EPS for the current fiscal year.
A number of equities analysts have recently commented on ZGNX shares. Leerink Swann reissued an “outperform” rating on shares of Zogenix in a report on Sunday, March 4th. Mizuho reaffirmed a “buy” rating and set a $51.00 target price on shares of Zogenix in a report on Wednesday, March 7th. ValuEngine raised shares of Zogenix from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. BidaskClub raised shares of Zogenix from a “hold” rating to a “buy” rating in a research report on Saturday, February 10th. Finally, JMP Securities assumed coverage on shares of Zogenix in a research report on Monday, November 27th. They set an “outperform” rating and a $56.00 price target for the company. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Zogenix currently has a consensus rating of “Buy” and an average target price of $46.40.
COPYRIGHT VIOLATION NOTICE: “Farallon Capital Management LLC Has $34.04 Million Holdings in Zogenix, Inc. (NASDAQ:ZGNX)” was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://ledgergazette.com/2018/03/14/zogenix-inc-zgnx-shares-bought-by-farallon-capital-management-llc.html.
Zogenix Company Profile
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.